Among the different class-specific ICI regimens, anti-PD-1 drugs (nivolumab), anti-PD-L1 drugs (atezolizumab) and anti-CTLA-4 drugs (ipilimumab) demonstrated a significant association with gastrointestinal disorders and metabolism disorders. This evidence concerns the gene CD274 and metabolic disease.